Acorda (ACOR) stock was up around 10% reaching over $28 in premarket trading. The stock is trading now around $27 with its gains oscillating between $2 – $2.20. The enthusiasm for ACOR seems to be about rumors that Biogen (BIIB) or possibly other Asian drug makers might have demonstrated the interest in Acorda.
What’s going on with Acorda?
In June 2017, the stock rallied on news about positive clinical trial results of the firm’s product INBRIJA (formerly CVT-301) for the treatment of OFF periods in patients with . . .